What’s Wrong with Race-Based Medicine? by Roberts, Dorothy E.
University of Pennsylvania Carey Law School 
Penn Law: Legal Scholarship Repository 
Faculty Scholarship at Penn Law 
Winter 1-1-2011 
What’s Wrong with Race-Based Medicine? 
Dorothy E. Roberts 
University of Pennsylvania Carey Law School 
Follow this and additional works at: https://scholarship.law.upenn.edu/faculty_scholarship 
 Part of the Bioethics and Medical Ethics Commons, Civil Rights and Discrimination Commons, Food 
and Drug Law Commons, Health and Medical Administration Commons, Health Law and Policy 
Commons, Medical Jurisprudence Commons, Public Health Commons, and the Science and Technology 
Law Commons 
Repository Citation 
Roberts, Dorothy E., "What’s Wrong with Race-Based Medicine?" (2011). Faculty Scholarship at Penn Law. 
435. 
https://scholarship.law.upenn.edu/faculty_scholarship/435 
This Article is brought to you for free and open access by Penn Law: Legal Scholarship Repository. It has been 
accepted for inclusion in Faculty Scholarship at Penn Law by an authorized administrator of Penn Law: Legal 
Scholarship Repository. For more information, please contact PennlawIR@law.upenn.edu. 
121_ROBERTS.DOCX 4/4/2011 8:03 AM 
 
1 
Articles 
What’s Wrong with Race-Based Medicine?: 
Genes, Drugs, and Health Disparities 
Dorothy E. Roberts* 
I. INTRODUCTION 
In June 2005, the Food and Drug Administration (FDA) 
announced a historic decision: it approved the first pharma-
ceutical indicated for a specific race.1 BiDil, a combination drug 
that relaxes the blood vessels, was authorized to treat heart 
failure in self-identified black patients. BiDil had been tested in 
the African-American Heart Failure Trial (A-HeFT) launched 
in 2001.2 A-HeFT enrolled 1,050 subjects suffering from ad-
vanced heart failure, all self-identified African Americans. A-
HeFT showed that BiDil worked; in fact, it worked so spectacu-
larly that the trial was stopped ahead of schedule. BiDil in-
creased survival by an astonishing 43 percent.3 Hospitaliza-
tions were reduced by 39 percent.4 It was a momentous 
                                                          
© 2011 Dorothy E. Roberts. 
*Kirkland & Ellis Professor, Northwestern University School of Law; faculty 
fellow, Institute for Policy Research. This article is based on the 2009–2010 
Deinard Memorial Lecture on Law & Medicine, delivered February 3, 2010. It 
is part of a larger book project, FATAL INVENTION: HOW SCIENCE, POLITICS, 
AND BIG BUSINESS RE-CREATE RACE IN THE TWENTY-FIRST CENTURY (forth-
coming, The New Press, 2011), supported by the National Science Foundation, 
the Robert Wood Johnson Foundation, and the Kirkland & Ellis Fund. I thank 
SJ Chapman for her assistance in preparing this article. 
 1. Press Release, U.S. Food and Drug Admin., FDA Approves BiDil 
Heart Failure Drug for Black Patients (June 23, 2005), available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm10
8445.htm. 
 2. See Ann L. Taylor et al., Combination of Isosorbide Dinitrate and Hy-
dralazine in Blacks with Heart Failure, 351 NEW ENG. J. MED. 2049, 2049 
(2004). 
 3. Press Release, supra note 1. 
 4. Id.; see also Common Questions: BiDil and the African American 
Heart Failure Trial (A-HeFT), http://www.bidil.com/pnt/questions.php#1 (last 
visited October 31, 2010). 
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accomplishment for Jay Cohn, the University of Minnesota 
cardiologist who invented BiDil and had pioneered vasodilators 
as an important treatment for heart failure. 
Given evidence of BiDil’s efficacy, but little evidence that 
race mattered to its efficacy, the FDA should have made one of 
two decisions: reject the request for race-specific approval or 
approve BiDil for all heart failure patients, regardless of race. 
Instead, the FDA put race at the center of its decision,5 spark-
ing controversy and paving the way for a new generation of ra-
cial medicines. 
No one is complaining that BiDil is available to people who 
will benefit from it. The problem is that BiDil was made avail-
able on the basis of race. Its racial label elicited three types of 
criticism: scientific, commercial, and political. I will discuss the 
first two controversies en route to what I consider the main 
problem with race-based medicine, its political implications. By 
claiming that race, a political grouping, is important to the 
marketing of drugs and that race-based drugs can reduce 
health disparities, which are caused primarily by social inequa-
lity, those who promote racialized medicine have made it a po-
litical issue. Yet, having made these political claims, these very 
advocates answer criticism by saying that we must put aside 
social justice concerns in order to improve minority health. This 
article explains why marketing pharmaceuticals on the basis of 
race is more likely to worsen racial inequities than cure them. 
II. RACE-SPECIFIC MEDICINE IS SCIENTIFICALLY 
FLAWED 
What does it mean for a pharmaceutical to be race-specific? 
A drug that is labeled for use by a particular race sounds like it 
has been developed based on scientific evidence that its ingre-
dients work for one group and not for others because of some 
underlying biological difference. But there is no such drug or 
scientific evidence supporting it. BiDil is a case in point. It does 
not contain new ingredients. It was not designed only for black 
people. Nor was it developed to target any particular genotype 
that only black people supposedly have or are more likely to 
have. Instead, it combined into a single pill two generic drugs 
that had been prescribed to patients regardless of race for over 
                                                          
 5. Press Release, supra note 1. 
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a decade.6 In fact, Dr. Cohn originally intended to market it to 
patients of any race who could benefit from it.7 There is not 
even scientific proof that BiDil works differently in black people 
because the clinical trial that tested BiDil enrolled only “self-
identified” African Americans.8 There is no basis for a compara-
tive statement if only one group has been tested. 
Its maker, NitroMed, asked the FDA to authorize BiDil as 
a race-specific drug on grounds that its clinical trial involving 
only African American patients showed a dramatic reduction in 
their heart failure deaths. In other words, the company argued 
that, because BiDil was tested only on blacks, the FDA should 
label it as a drug for blacks only. As Jane Kramer, NitroMed’s 
vice president of corporate affairs, would later explain, “That 
doesn’t mean that it works in all African Americans and it 
doesn’t mean that it doesn’t work in other patients. It just 
means that we know it clearly works in African Americans.”9 
This kind of logic had never resulted in a racial indication 
before. In the past, the FDA has had no problem generalizing 
clinical trials involving white people to approve drugs for eve-
ryone. That is because it believes that white bodies function 
like human bodies. However with BiDil, a clinical trial involv-
ing all African Americans could only serve as proof of how the 
drug works in blacks. By approving BiDil only for use in black 
patients, the FDA emphasized the supposed distinctive, and 
substandard, quality of black bodies.10 It sent the message that 
black people cannot represent all of humanity as well as white 
people can. 
Why did BiDil work especially well in black patients? Ni-
troMed had no scientific evidence to answer this question, but 
it speculated that the mechanism had to do with biological dif-
ference. In a March 2001 press release, NitroMed explained 
                                                          
 6. Taylor, supra note 2, at 2049. 
 7. See Method of Reducing Mortality Associated with Congestive Heart 
Failure Using Hydralazine and Isosorbide Dinitrate, U.S. Patent No. 
4,868,179 (filed Apr. 22, 1987). 
 8. Taylor, supra note 2, at 2050. 
 9. Turna Ray, HHS Draft Report Suggests Genetic Test for BiDil, Ni-
troMed Does Not Rule Out Dx, PHARMACOGENOMICS REP. (Apr. 4, 2007), 
http://www.genomeweb.com/dxpgx/hhs-draft-report-suggests-genetic-test-bidil-
nitromed-does-not-rule-out-dx. 
 10. See, e.g., Rene Bowser, Racial Profiling in Health Care: An Institu-
tional Analysis of Medical Treatment Disparities, 7 MICH. J. RACE & L. 79, 113 
(2001); Rene Bowser, Race as a Proxy for Drug Response: The Dangers and 
Challenges of Ethnic Drugs, 53 DEPAUL L. REV. 1111, 1126 (2004). 
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that BiDil works especially well for African Americans because 
“observed racial disparities in mortality and therapeutic re-
sponse rates in black patients may be due in part to ethnic dif-
ferences in the underlying pathophysiology of heart failure.”11 
NitroMed sought FDA approval based on pure speculation that 
race was a good enough proxy for some underlying genetic or 
pathophysiological difference without conducting any investiga-
tion whatsoever to test this claim. The researchers who re-
ported BiDil’s effectiveness for African American heart patients 
recognized this flaw and simply promised to correct it at some 
future time.12 
The FDA expounded the race-as-proxy theory in a January 
2007 article in Annals of Internal Medicine explaining its ap-
proval of BiDil. “We hope that further research elucidates the 
genetic or other factors that predict the usefulness of hydrala-
zine hydrochloride-isosorbide dinitrate,” the author wrote.13 
“Until then, we are pleased that one defined group has access 
to a dramatically life-prolonging therapy.”14 In other words, a 
racially-defined group could serve as a temporary substitute for 
the yet undiscovered genetic or other factor that identifies who 
will benefit from BiDil. 
The issue crystallized during the FDA hearing on BiDil in 
a debate between two Advisory Committee members. Vivian 
Ota Wang from the National Institutes of Health’s National 
Human Genome Research Institute challenged the use of race 
in the A-HeFT trial as a proxy for an underlying biological trait 
that explained how BiDil worked. “There is a presumption here 
that somehow this self-identified social identifier is somewhat 
equivalent or representative of a biological process, and I am 
not sure it really is,” Ota Wang pointed out.15 “We need to real-
                                                          
 11. Jonathan Kahn, How A Drug Becomes “Ethnic”: Law, Commerce, and 
the Production of Racial Categories in Medicine, 4 YALE J. HEALTH POL’Y L. & 
ETHICS 1, 2 (2004) (citing Press Release, NitroMed, NitroMed Initiates Con-
firmatory BiDil Trial in African American Heart Failure Patients (Mar. 
17, 2001)). 
 12. Denise Gellene, Heart Pill Intended Only for Blacks Sparks Debate, 
L.A. TIMES, June 16, 2005, at C1. 
 13. Robert Temple & Norman L. Stockbridge, BiDil for Heart Failure in 
Black Patients: The U.S. Food and Drug Administration Perspective, 146 
ANNALS OF INTERNAL MED. 57, 61 (2007). 
 14. Id. 
 15. Transcript of Department of Health and Human Services Food and 
Drug Administration Center for Drug Evaluation and Research, Cardiovascu-
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ly carefully look at the issue of self-identified racial categories 
because if the assumption is that these population differences 
are biological, the self-identified population is a social and po-
litical construct.”16 The Committee Chair, Cleveland Clinic car-
diologist Steven Nissen, dismissed Ota Wang’s concerns. “We 
are using self-identified race as a surrogate for genomic-based 
medicine and I don’t think that is unreasonable.” Nissen said.17 
“I wish we had the genetic markers . . . to decide who is going to 
respond to what drug but, in the absence of that, we have to 
use the best available evidence, . . . and that evidence was used 
in this trial and it worked.”18 Later, Dr. Nissen more bluntly 
reiterated, “We’re using self-identified race as a surrogate for 
genetic markers.”19 Nissen dismissed the worry that this ratio-
nale for approving a race-specific drug would reinforce a genetic 
definition of race by asserting, “Drugs aren’t racist; people 
are.”20 
Not only was the racial indication scientifically flawed, but 
race became a reason for lowering the FDA’s scientific stan-
dards. In 1989, Dr. Cohn obtained a patent on a “method of re-
ducing mortality associated with congestive heart failure.”21 
The patent made no mention of race. In 1996, the company he 
licensed the rights to submitted a New Drug Application for 
BiDil to the FDA. Like Cohn’s patent application, this applica-
tion for marketing approval did not mention race. Its evidence 
of the drug’s efficacy consisted of a retrospective analysis of 
clinical trials Cohn conducted in the 1980s. The FDA Advisory 
Committee that reviewed the application was not convinced.22 
The issue was not BiDil’s effectiveness; it was the FDA’s statis-
tical standards. The Advisory Committee found that the reana-
lysis of old data, which were not collected to test a new drug for 
FDA approval, failed to meet the narrow criteria for statistical 
                                                          
lar and Renal Drugs Advisory Committee, at 99 (June 16, 2005) (statement of 
Dr. Vivian Ota Wang), available at 
http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4145T2.pdf [herei-
nafter Committee Transcript]. 
 16. Id. at 357. 
 17. Id. at 355 (statement of Dr. Steven Nissen). 
 18. Id. at 360. 
 19. FDA May OK Advisory Panel Call for African American Heart Drug, 
FDA WEEK (Inside Wash. Publishers, Washington, D.C.), Jun. 17, 2005. 
 20. Committee Transcript, supra note 15 at 354 (statement of Dr. Steven 
Nissen). 
 21. U.S. Patent No. 4,868,179. 
 22. Temple & Stockbridge, supra note 13, at 59. 
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significance.23 Another problem was that BiDil would be pre-
scribed as an adjunct to standard ACE inhibitor and beta 
blocker therapies, therapies that were not combined with the 
BiDil ingredients in the earlier trials. Consequently, the FDA 
denied approval in 1997.24 
During the 2004 FDA hearing on Cohn’s application to 
market BiDil as a race-specific drug, the question of statistical 
standards was raised again. Ota Wang and Nissen also differed 
on the standards the FDA should use to evaluate BiDil. Nissen 
took the position that the remarkable improvement in health 
experienced by the A-HeFT patients on BiDil should outweigh 
concerns about the statistical strength of trial data. “I have to 
approve a drug when I think there’s evidence you can reduce 
mortality by 43 percent,” he said, “As a clinician, I find the evi-
dence more than adequate to vote for approval.”25 Comparing 
heart failure among African Americans to an “orphan disease,” 
Nissen argued that “you make some adjustments sometimes 
because you want to encourage trials in special populations and 
diseases which are of public health importance which we have 
few therapies for.”26 In other words, to Nissen, heart failure 
suffered by African Americans was a special type of illness that 
warranted exceptions to the rules, as in the case of rare medical 
conditions. 
Ota Wang objected to the “notion that for some types of re-
search, for some types of communities or populations we can 
actually lower the bar in terms of scientific integrity that we 
are using to evaluate the research.”27 In response, Nissen reite-
rated the orphan disease analogy. “So, if you are developing a 
drug for a disease and there are not many people that have it, 
you get some points for doing that.” he said. “I am arguing that 
it is not unreasonable public policy to make some adjustment 
                                                          
 23. Id. 
 24. U.S. FOOD AND DRUG ADMINISTRATION, CLINICAL REVIEW: 
HYDRALAZINE HCL AND ISOSORBIDE DINITRATE (2004), available at 
http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4145B2_01_03_FDA-
Medical-Addendum.pdf; see also Committee Transcript, supra note 15, at 11–
14. 
 25. Aaron Lorenzo, FDA Panel Votes 9-0 to Support BiDil’s Clearance, 
BIOWORLD TODAY, June 17, 2005. 
 26. Jonathan Kahn, Exploiting Race in Drug Development: BiDil’s Interim 
Model of Pharmacogenomics, 38 SOC. STUD. OF SCI. 737, 746 (2008). 
 27. Committee Transcript, supra note 15, at 304 (statement of Dr. Steven 
Nissen). 
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for that.”28 Statistical weaknesses in the data that ordinarily 
posed problems for FDA approval were overlooked because Bi-
Dil was a drug for black people. Apparently, Dr. Nissen was not 
referring to heart failure in general, a common ailment that is 
far from an “orphan” disease, but to black people’s heart fail-
ure. The very issues about statistical data that led the FDA to 
deny approval for BiDil when it was for the general population 
were now overlooked because BiDil had become a race-specific 
drug. 
Perhaps the overwhelming evidence from the A-HeFT trial 
that BiDil was beneficial for many patients was a compelling 
reason to discount the statistical concerns and make it widely 
available on the market. The stunning trial results gave the 
FDA grounds to approve the drug without insisting on its sta-
tistical rules or further investigation of why BiDil worked so 
well, but what the A-HeFT trial did not do was give the FDA 
grounds to base its decision on race. We should be concerned 
that the FDA’s acceptance of race-specific drugs will turn into a 
rationale for “lowering the bar” of the scientific standards the 
agency usually applies in evaluating new drugs. 
III. RACE-SPECIFIC MEDICINE IS COMMERCIALLY 
MOTIVATED 
A second problem with racial indications for pharmaceuti-
cals is that they are guided by the market and not by science. 
Race is becoming a niche market that gives pharmaceutical 
companies an opportunity to extract new profits from existing 
drugs. Again, BiDil provides an illustration. 
Recall that the FDA denied Cohn’s original application to 
market BiDil without regard to race. With his original race-
neutral patent due to expire in less than 10 years, Cohn needed 
a strategy for salvaging his pharmaceutical venture. Cohn’s 
second chance came from re-conceiving BiDil as a race-specific 
drug.29 It was only after the FDA rejection that Cohn turned 
BiDil—the exact same drug that he had patented without re-
gard to race—into a therapy for African Americans. Cohn sub-
mitted a new patent for BiDil with a critical difference from the 
original one. The new patent added the key language: the 
“present invention provides methods for treating and prevent-
ing mortality associated with heart failure in an African Amer-
                                                          
 28. Id. at 305–06. 
 29. Kahn, supra note 11, at 3. 
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ican patient.”30  The new patent, issued in 2000, lasts until 
2020, buying thirteen more years of intellectual property con-
trol over the drug. 
NitroMed’s success at using race to gain FDA and patent 
approval, as well as support from influential political players, 
signaled the potential profitability of race-specific drugs. Legal 
scholar Jonathan Kahn argues that BiDil’s racial labeling gave 
the pharmaceutical industry “a new model of how to exploit 
race in the marketplace by literally capitalizing on the racial 
identity of minority populations,” providing “a cheaper, more 
efficient way to gain the US Food and Drug Administration’s 
approval for drugs.”31 Supporting his view is evidence of the 
growing use of race as a genetic category to obtain patent pro-
tection. Using the U.S. Patent Office database, Kahn reviewed 
gene-related patent applications filed between 1976 and 2005 
that employed racial or ethnic categories. Kahn discovered a 
five-fold increase in racial patents during that period. Race was 
not mentioned in any application filed in 1976–1997.32 From 
1976–2005 twelve gene-related patents were issued using race 
or ethnicity, and from 2001–2005 sixty-five gene-related pa-
tents applications were filed using race or ethnicity.33 
Using racial categories to patent an invention and to carve 
out a racially-defined market for it is nothing new. There is a 
long history, dating back to the 1800s, of patenting all sorts of 
products that involve race: chemicals to straighten kinky hair, 
creams to lighten dark skin, and toys that celebrate or mock 
people of color.34 For example, a patent from 1940 for an arcade 
game featured a figure of a “negro stealing a chicken” as a tar-
get.35 “As soon as the target is initially moved, with the negro 
moving toward the hen house, a successful hit will cause him to 
reverse his direction of movement and leave the hen house,” the 
                                                          
 30. Methods of Treating and Preventing Congestive Heart Failure With 
Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate, 
U.S. Patent No. 6,465,463 (filed Sep. 8, 2000) (emphasis added). 
 31. Kahn, supra note 26, at 737–38 (2008); see also Jonathan Kahn, The 
Politics of Patenting Race, 20 GENE WATCH 3, 3 (2007) (arguing that BiDil is 
serving as a model for the “strategic use of race as a genetic category to obtain 
patent protection and drug approval.”). 
 32. Kahn, supra note 31, at 4. 
 33. Id. 
 34. Shubha Ghosh, Race-Specific Patents, Commercialization, and Intel-
lectual Property Policy, 56 BUFF. L. REV. 409, 413 (2008). 
 35. Id.  
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inventor explained.36 The Civil Rights Movement ushered in 
patents for dolls, games, and teaching materials that celebrated 
diversity, ethnic holidays, and civil rights leaders. A more re-
cent patent filed in 2006 for a device that quickly removes nat-
ural or synthetic braids that have been attached to human hair 
claims to benefit African Americans because they “genetically 
have hair that resists the formation of longer lengths.”37 
Race and ethnic heritage are used by patent applicants in a 
variety of ways, some more harmful than others. The problem 
with recent gene-related patents is that they treat race as a 
biological category. Treating racial identity as a component of a 
genetic commodity further solidifies the view that race is bio-
logical. “The patent process takes race as a social category and 
recodes it as ‘natural,’” Kahn writes.38 The growing number of 
biomedical studies and patents that rely on race suggests that 
biotech companies are poised to launch a new generation of ra-
cial pharmaceuticals. 
It would be naïve to believe that, given our market-driven 
system, biomedical research can proceed without private fund-
ing and without converting discoveries into marketable prod-
ucts. But it is equally naïve to ignore the influence of pharma-
ceutical money on the way biomedical research is conducted. 
The A-HeFT researchers surely were motivated by a desire to 
alleviate the suffering of black heart failure patients, but their 
ties to the pharmaceutical industry helped to steer their path to 
a cure. 
My quarrel with the commercial aspects of BiDil’s devel-
opment is not that the people involved made money. Congress 
has ensured that profit is the central incentive for the pharma-
ceutical industry to research and market medications. In his 
commentary on my lecture, Jay Cohn conceded that “there’s a 
commercial benefit to this—of course. How else do drugs get 
developed in this country except on the basis of commercial po-
tential? So if you want to criticize that, you can criticize the en-
tire economic strategy in America and maybe Dorothy would 
like to do that.”39 It is one thing for biomedical researchers and 
                                                          
 36. Id. at 441. 
 37. Id. at 431. 
 38. Jonathan Kahn, Patenting Race in a Genomic Age, in REVISITING 
RACE IN A GENOMIC AGE, 129, 131 (Barbara A. Koenig et al. eds., 2008). 
 39. Jay Cohn, Director, Rasmussen Center for Cardiovascular Disease 
Prevention, Commentary at The Deinard Memorial Lecture on Law & Medi-
cine (Feb. 3, 2010) (transcript on file with Minnesota Journal of Law, Science 
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pharmaceutical companies to profit from scientific innovation; 
it is quite another for the profit motive to steer the science that 
is being innovated. Commercial interests induce pharmaceuti-
cal companies to exaggerate or invent the therapeutic impor-
tance of race. NitroMed did not make money from a drug that 
was developed to treat heart failure in black patients. It made 
money by converting a drug for heart failure into a drug for 
African Americans based on unscientific claims about racial dif-
ference. 
IV. RACE-BASED MEDICINE IS POLITICALLY 
DANGEROUS 
Despite these criticisms, is it not a good thing that BiDil is 
on the market? Supporters of race-specific drugs counter the 
scientific and commercial challenges I discuss by arguing that 
these drugs are critical to advancing health in two very impor-
tant ways: they are a step toward developing personalized med-
icine, and they are immediately addressing health disparities 
based on race.40 
I argue that it is precisely these two claims that make race-
based medicine not only scientifically flawed but politically 
dangerous. By reinforcing a biological definition of race and 
cure for health disparities that are false, race-based medicine 
supports a new biopolitics of race that threatens to make health 
and other social inequalities even worse. 
For the last decade, genetic scientists have promised to 
soon develop personalized medicines that will enable doctors to 
predict, diagnose, and treat illnesses according to each patient’s 
own unique genome.41 Researchers in the field of pharmacoge-
nomics, which studies the genetic origins of disease and diffe-
rential responses to medications, are trying to develop “tai-
lored” drugs that are safer and more effective than 
conventional medicines. But a decade after completion of the 
Human Genome Project, researchers have failed to discover the 
genes that cause common diseases, which were predicted to en-
able the development of gene-targeted medicines.42 “There is 
                                                          
& Technology). 
 40. Kahn, supra note 26, at 748. 
 41. See M. Gregg Bloche, Race-Based Therapeutics, 351 NEW ENG. J. MED 
2035–37 (2004). 
 42. Nicholas Wade, A Decade Later, Genetic Map Yields Few Clues, N.Y. 
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absolutely no question that for the whole hope of personalized 
medicine, the news has been as bleak as could be,” summed up 
molecular biologist David Goldstein, director of Duke Universi-
ty’s Center for Human Genome Variation, in September 2008.43 
Despite statistically linking hundreds of common variants to 
various diseases, scientists discovered that they account for on-
ly a tiny fraction of the genetic risk.44 Instead, most common 
diseases are caused by a host of rare genetic variants that 
evade detection by genome-wide association studies. 
Despite the lack of genetic data—or perhaps because of it—
race has become the magic fix to bridge the gap between the 
promise and disappointment of personalized medicine. Phar-
macogenomic researchers treat race as a crucial first step to 
producing designer drugs because, they argue, race can serve 
as a proxy for individual genetic difference.45 Until science is 
able to match therapies to each individual’s unique genotype, 
race functions as a handy surrogate. 
The FDA’s press release announcing its approval of BiDil 
stated that the decision “represent[ed] a step toward the prom-
ise of personalized medicine.”46 But what did BiDil have to do 
with personalized medicine? It was not a drug designed for 
black people at all, let alone one tailored to match some race-
based genetic difference. It was developed to treat heart failure 
regardless of race and regardless of genetics. Yet despite hav-
ing nothing to do with pharmacogenomics, “the step toward 
personalized medicine” claim became one of the leading ratio-
nales for race-based medicine. In FDA Week, Michael Warner, a 
former regulatory affairs specialist for the Biotechnology In-
dustry Organization, falsely asserted that “BiDil is the first 
time, the highest profile time, the model of ‘let’s identify a tar-
get population and let’s develop a drug for that population’ has 
been pursued.”47 
A second basis for defending race-based pharmaceuticals is 
the claim that their health benefits outweigh their power to 
reinforce race as a biological category. Prominent African 
American scientists, doctors, and advocates endorsed BiDil to 
                                                          
TIMES, June 12, 2010, at A1. 
 43. Nicholas Wade, A Dissenting Voice as the Genome is Sifted to Fight 
Disease, N.Y. TIMES, Sept. 16, 2008, at F3. 
 44. Wade, supra note 42. 
 45. Temple & Stockbridge, supra note 13, at 58. 
 46. Press Release, supra note 1. 
 47. Kahn, supra note 26, at 740. 
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redress past discrimination against African Americans in medi-
cal treatment and access to health care.48 Ever since their en-
slavement in the United States, African Americans have been 
victims of both medical abuse, such as the infamous syphilis 
study in Tuskegee, Alabama, and medical neglect.49 BiDil sup-
porters argued that a race-specific drug fulfilled a longstanding 
demand that science attend to the particular needs of African 
Americans whom historically had been excluded from good 
medical care and clinical trials while suffering disproportio-
nately from heart disease. Representative Donna Christenson 
implored the FDA to approve BiDil as a remedy for medical 
wrongs against African Americans “for whom treatment has 
been denied and deferred for 400 years.”50 
Many used the health disparities as a reason to ignore the 
scientific flaws in race-based medicine. Gary Puckrein, execu-
tive director of the National Minority Health Month Founda-
tion, has championed BiDil as an important response to high 
rates of heart disease among African Americans. Although he 
acknowledged “[c]oncern about the medical and scientific valid-
ity of the concept of race,” he dismissed such concern as “under 
present circumstances, impractical.”51 Similarly, Keith Ferdi-
nand, chief science officer of the Association of Black Cardiolo-
gists, wrote that “race lacks any true biologic definition,”52 but 
BiDil is a “life-saving drug”53 that addresses “evidence of racial 
and ethnic differences in cardiac care in the United States 
which may significantly affect health outcomes.”54 In other 
words, these BiDil advocates argue that the urgency of address-
ing the African American health crisis with race-specific drugs 
overrides objections that race is a social and not a genetic 
grouping. 
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When I stated at an April 2006 conference on race-based 
therapeutics at the Massachusetts Institute of Technology that 
there was no consensus among African Americans on the bene-
fits of these pharmaceuticals, Juan Cofield, president of the 
National Association for the Advancement of Colored People 
(NAACP) New England branch, stood up in the audience and 
objected. “There is a consensus supporting BiDil,” he stated, 
“The NAACP supports it, the Association of Black Cardiolo-
gists, and the Black Congressional Caucus supports it.” “There 
isn’t even a consensus on BiDil among the black people in this 
room,” I replied. That may have elicited laughter from the au-
dience, but it did not assuage Cofield. “Young lady,” he re-
sponded, “you are jeopardizing the lives of black people.” Ac-
cording to Cofield, I had no right to suggest that blacks are not 
united behind promoting racial therapeutics. 
Upon further investigation, I discovered that in December 
2005, the NAACP announced its partnership with NitroMed “to 
implement measures to narrow health disparities that exist be-
tween African Americans and Caucasians . . . .”55 As part of this 
alliance, NitroMed promised the NAACP a three-year $1.5 mil-
lion grant.56 In return, the NAACP vigorously promoted BiDil 
in black communities as a life-saving drug for African Ameri-
cans.57 NitroMed’s Chief Executive Office, Dr. Michael Loberg, 
described of the partnership’s chief aims as “together with the 
NAACP . . . doing our part to remove all barriers to access to 
BiDil.”58 
This was not the first time I had heard this accusation. At 
a 2005 University of Minnesota race in biomedical research 
conference, Jay Cohn objected to my legal and moral concerns 
about labeling drugs by race. Another speaker, Georgetown 
bioethicist Gregg Bloche, although also opposed to racial labe-
ling, asked how I could justify sacrificing the lives of black 
grandmothers merely to avoid classifying people by race.59 I 
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was shocked four years later to hear Jay Cohn on a Radio Lab 
broadcast say, “And there was a very well known law professor 
who said, ‘I would rather die from heart failure than take Bi-
Dil!’” (referring to my talk at the conference).60 Fortunately, the 
host intervened to say, “Well, that’s not quite what she said,” 
and played my actual words: “I would be terrified about a doc-
tor making a diagnosis like that based on his view of me as be-
longing to a particular racial category.”61 Again, in his commen-
tary on my 2009 lecture, Dr. Cohn charged that “the hostility 
that has grown in the community against this therapy has im-
paired its use, and, therefore, the vast majority of blacks with 
heart failure are not receiving life-prolonging therapy.”62 
These activists and researchers with ties to the pharma-
ceutical industry try to stifle criticism of racial medicine by por-
traying objections as roadblocks to African Americans’ access to 
lifesaving treatment.63 They imply that objecting to race-
specific medicine is tantamount to denying black patients the 
medicine they need. Behind this argument is the false assump-
tion that it is impossible to develop drugs that benefit blacks 
without classifying people by race. 
It is unfair to accuse people who oppose racial labeling of 
trying to keep lifesaving drugs from dying patients. No critic of 
race-specific medicine seeks to deny lifesaving drugs to African 
American people.64 We never argued that BiDil should be with-
held from the market. Just the opposite is true: we argued that 
if it were to be marketed, it should be made more widely avail-
able—without regard to race. We simply see no justification for 
marketing medicines according to race and worry about their 
potential to divert attention away from more significant social 
reasons for health disparities. Studying and eliminating the so-
cial determinants of health inequities is a far more promising 
course than searching for race-specific genetic differences. 
Portraying BiDil as a solution to a racial gap in mortality 
implies the gap stems from racial differences in disease and 
drug response. Adding a genetic explanation for this difference 
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attributes health disparities to flaws inside black people’s bo-
dies rather than to flaws in the society they live in. It supports 
the increasingly popular but misguided view that the tiny per-
centage of genetic difference among human beings is distri-
buted by race and that this difference creates inequities in 
health. 
In his commentary on my lecture, Dr. Cohn objected that I 
raised “concerns that all of us have about inequality of health-
care that BiDil was never developed to address.”65 Although 
Cohn belatedly protests the insertion of health disparities into 
the debate about BiDil, it was BiDil advocates who first relied 
on the mortality gap between blacks and whites to gain support 
for the drug and who painted BiDil was a response to centuries 
of discrimination against African Americans. As Susan Reverby 
has observed, the “shadow of Tuskegee”66 hung over the FDA 
hearing and put pressure on the advisory committee to approve 
BiDil as a therapy for black people.67 
While listening to African American advocates for race-
specific medicine, the FDA Advisory Committee ignored the 
evidence presented by Dr. Charles Rotimi, a researcher at 
Howard University’s Human Genome Center, that showed high 
rates of hypertension among blacks stemming from environ-
mental rather than genetic causes.68 To Dr. Rotimi, it made no 
sense to conclude that blacks are “selectively acquiring bad 
genes” for the numerous conditions marked by racial gaps in 
mortality.69 It is implausible that one race of people evolved to 
have a genetic predisposition to heart failure, hypertension, in-
fant mortality, diabetes, and asthma. There is no evolutionary 
theory that can explain why African ancestry would be geneti-
cally prone to practically every major common illness. “There 
must be something in our social environment that drives people 
toward poor health, and only by addressing that can we reduce 
health disparity,” Dr. Rotimi concluded.70 
Many scientific studies that show that racially unequal 
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health outcomes stem from unequal social conditions support 
Dr. Rotimi’s views.71 Some, like a study of racial gaps in breast 
cancer mortality in Chicago, show that the geographical con-
centration and historical changes in racial health disparities 
could not possibly stem from genetic difference.72 White women 
in Chicago are slightly more likely than black women to get 
breast cancer.73 Black women are twice as likely to die from 
it.74 That is a startling statistic by itself. But what is equally 
shocking is that Chicago’s black and white breast cancer mor-
tality rates were identical in 1980. The astounding gap 
emerged over the course of the next twenty-five years.75 The 
most likely explanation is that black women did not have 
access to the technologies and therapies that lowered white 
women’s cancer mortality rate.76 Moreover, the disparity in 
breast cancer mortality in New York City is only fifteen per-
cent, making the racial gap in Chicago ten times greater than 
in New York—a disparity unexplained by genetic difference.77 
Dr. Richard Cooper’s global comparison of hypertension 
similarly refutes a genetic explanation for race-based health 
inequities. His study revealed that blacks in Nigeria and Ja-
maica have rates of hypertension similar to that of whites in 
the United States and much lower than that of African Ameri-
cans.78 Perhaps Nigerians and African Americans are genetical-
ly prone to high blood pressure, but there is something in the 
environment that is causing elevated rates in this country. But 
that is just the point: if our goal is eliminating the gap between 
white and black hypertension in the United States, our focus 
should be on the social causes of the gap. Continuing to hunt 
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for a genetic component of racial differences only distracts us 
from the more relevant issue of identifying and tackling the 
preventable causes of hypertension, which have a similar im-
pact regardless of race. This approach would help everyone who 
lives in conditions that cause high rates of hypertension. 
Perhaps the most powerful evidence of the importance of 
social determinants is the relationship between an entire na-
tion’s health and its level of inequality. Numerous studies 
tracking the health of people along the social ladder show that 
health gradually worsens as socioeconomic status, including 
race, declines.79 In their recent book, The Spirit Level, Richard 
Wilkinson and Kate Pinkett present remarkably consistent 
evidence of “a very strong tendency for ill-health and social 
problems [including life expectancy and infant mortality] to oc-
cur less frequently in the more equal countries.”80 To put it 
another way, “Health and social problems are indeed more 
common in countries with bigger income inequalities.”81 People 
in Japan, Sweden, and Norway live longer, are less obese, and 
have fewer teenage births than people in the United States, the 
United Kingdom, and Australia because their societies are 
more equal.82 The United States is unhealthier, despite spend-
ing far more money on genetic research and drugs. The reason 
is not that the United States has not done enough genetic re-
search. It is because the United States has more social inequa-
lity and has not done enough to eliminate it. 
Instead, attention has turned sharply toward the possible 
genetic reasons for drug effectiveness and health disparities. 
The NitroMed research team began searching in 2005 for the 
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gene that explained how BiDil worked—after it was approved 
as a race-specific drug. The Genetic Risk Assessment in Heart 
Failure Trial (GRAHF) compared the frequency of aldosterone 
synthase (CYP11B2) alleles in 354 patients who participated in 
A-HeFT to their frequency in white participants in the Genetic 
Risk Assessment of Cardiac Events (GRACE) study conducted 
at the University of Pittsburgh.83 Activation of aldosterone ap-
pears to hasten the progression of heart failure. The GRAHF 
study found that the -344 T/C promoter polymorphism of 
CYP11B2 influenced clinical outcomes in the African American 
patients and that it was more common in African American pa-
tients than in the white patients who participated in GRACE. 
The authors observed that these findings “suggest that the ge-
netic variation in aldosterone production may contribute” to dif-
ferences in heart failure rates between blacks and whites. “In 
determining optimal heart failure treatment for an individual, 
race is likely a surrogate marker for differences in genetic 
background,” they concluded.84 
By comparing genotypes in black and white patients, the 
researchers seemed stuck on finding a biological mechanism 
based on race. NitroMed’s Vice President of Corporate Affairs 
stated in 2007 that the company might eventually use the ge-
netic data to develop a diagnostic test for BiDil, though it is not 
clear what financial incentive it had to invest in genetic screen-
ing if it could use race instead. NitroMed researchers had a 
vested interest in finding racial differences that could justify 
FDA approval. By leaping to a genetic explanation, they forec-
losed a potentially more fruitful investigation of the environ-
mental factors that separate white and black health—and that 
could improve prevention of heart disease for everyone. 
Researchers still do not know why blacks get and die from 
heart failure at a much earlier age than whites.85 But if I were 
a scientist, I would start looking at the effects of young black 
men’s seventy-five per cent chance of being incarcerated in 
some cities.86 Heart disease researchers should be more inter-
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ested in the fact that black men are seven times more likely 
than whites to be imprisoned in this country than the less sig-
nificant genetic differences many are so fixated on.87 
Attributing health inequities to genetic difference is part of 
a broader trend, what I call a new biopolitics of race, that is fo-
cusing on race at the molecular level while discounting its im-
pact on society.88 At the other end of the political spectrum 
from the African American advocates I quoted earlier, are con-
servatives who claim that racial differences are real at the ge-
netic level and also charge their critics with relying on political 
ideology rather than science.89 They argue that race is a natu-
ral category that became politicized only in the last few decades 
because of post-civil rights identity politics.90 This ignores the 
real origins of racial classifications that accommodated Euro-
pean, and later American, imperialism and slavery—the quin-
tessential example of using science to achieve political ends. 
Conservatives point to racial medicine as scientific confirma-
tion of racial differences that liberals have denied in order to be 
politically correct. 
Sally Satel, a fellow at the American Enterprise Institute, 
has long defended the use of race in medical practice in re-
sponse to biological differences between members of different 
racial groups. At a 2004 American Enterprise Institute Sympo-
sium entitled, Race, Medicine, and Public Policy, she concluded, 
“It is evident that disease is not colorblind, and therefore doc-
tors should not be either.”91 Not surprisingly, Satel supports 
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race-specific pharmaceuticals. “Social race is the phenomenon 
constructionists have in mind . . . . Biological race, however, is 
what BiDil’s developers are concerned with—that is, race as 
ancestry.”92 
According to this view, racial differences are real at the 
molecular level and merely constructed in society; therefore, 
doctors and researchers cannot be colorblind, but social policy 
should be. Genomic science, these conservatives argue, now 
gives people license to act on biological differences between rac-
es to better understand their health and identities. In this in-
genious twist of political logic, those who criticize racial medi-
cine because of its social impact are seen as interfering with 
health on the basis of racial ideology. 
A renewed trust in inherent racial differences provides a 
convenient but false explanation for persistent inequities de-
spite the end of de jure discrimination. It is also the perfect 
complement to social policies that implement the claim that 
racism has ceased to be the cause of African Americans’ un-
equal status. Race consciousness in social programs like affir-
mative action is under assault at the very moment that race 
consciousness in medicine is ascending. As Chief Justice Ro-
berts stated in one of several recent Supreme Court decisions 
chiseling away at government’s use of race to address institu-
tionalized inequality, “The way to stop discrimination on the 
basis of race is to stop discriminating on the basis of race.”93 
There is a long history of using a biological definition of 
race to make social inequities seem natural—the result of inhe-
rent difference instead of societal injustice. As Evelynn Ham-
monds has noted, “[T]he appeal of a story that links race to 
medical and scientific progress is in the way in which it natura-
lizes the social order in a racially stratified society such as 
ours.”94 
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While the racial gap in life expectancy widens,95 owing 
largely to the government’s failure to address structural inequi-
ties, the poor health of African Americans opens new markets 
for pharmaceutical companies. The claim that race-based bio-
technologies will shrink the gap based on genetic difference is a 
powerful way to deflect concerns about their unjust social im-
pact and the social inequality that actually drives poor minority 
health. We should be against an approach that promotes indi-
vidual health through technological cures as a way of ignoring 
larger social inequities. This view sets up a false dichotomy be-
tween health and social justice: it treats health and justice as 
opposing values, weighs them against each other, and declares 
health the winner. It hides the social factors that determine 
health not only for individuals but for the entire nation. Letting 
health trump social justice does not really improve the welfare 
of most people; it supports the interests of big business and the 
most privileged members of society. 
The promotion of race-based medicine misrepresents the 
relationship between genes, drugs, and health disparities. Of 
course, pharmaceuticals can help improve sick people’s health 
and effective pharmaceuticals should be available to people 
who would benefit from them. But health inequities are not 
caused by genes and cannot be eliminated with drugs. Promot-
ing race-based medicine with the myth that poor minority 
health is caused by genetic difference will only widen the gap, 
diverting us from the real solution. It makes no sense to put 
aside social justice concerns in order to improve minority 
health. A more just society would be a healthier one. 
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